An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence and risk of major CV events, malignancies, and venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with tofacitinib compared to tumor necrosis factor (TNF) inhibitors, depending on the level of CV risk at the initiation of this therapy. The authors used data from the ORAL Surveillance study.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
